Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Healthtrust
Johnson and Johnson
AstraZeneca
Chinese Patent Office
Argus Health
Chubb
Covington
McKesson
Citi

Generated: October 24, 2017

DrugPatentWatch Database Preview

Tamoxifen citrate - Generic Drug Details

« Back to Dashboard

What are the generic sources for tamoxifen citrate and what is the scope of tamoxifen citrate patent protection?

Tamoxifen citrate
is the generic ingredient in three branded drugs marketed by Teva, Midatech Pharma Us, Roxane, Actavis Labs Fl Inc, Mylan, Pharmachemie, Ivax Sub Teva Pharms, Astrazeneca, Apotex, Mayne Pharma, and Aegis Pharms, and is included in twelve NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Tamoxifen citrate has seven patent family members in seven countries.

There are sixteen drug master file entries for tamoxifen citrate. Eleven suppliers are listed for this compound.

Summary for Generic Name: tamoxifen citrate

US Patents:1
Tradenames:3
Applicants:11
NDAs:12
Drug Master File Entries: see list16
Suppliers / Packagers: see list11
Bulk Api Vendors: see list47
Clinical Trials: see list917
Patent Applications: see list7,915
Therapeutic Class:Antineoplastics
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:tamoxifen citrate at DailyMed

Pharmacology for Ingredient: tamoxifen citrate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan
TAMOXIFEN CITRATE
tamoxifen citrate
TABLET;ORAL074732-002Feb 20, 2003ABRXNoNo► Subscribe► Subscribe► Subscribe
Mayne Pharma
TAMOXIFEN CITRATE
tamoxifen citrate
TABLET;ORAL075797-001Feb 20, 2003ABRXNoNo► Subscribe► Subscribe► Subscribe
Mylan
TAMOXIFEN CITRATE
tamoxifen citrate
TABLET;ORAL074732-001Feb 20, 2003ABRXNoNo► Subscribe► Subscribe► Subscribe
Actavis Labs Fl Inc
TAMOXIFEN CITRATE
tamoxifen citrate
TABLET;ORAL076179-002Feb 20, 2003DISCNNoNo► Subscribe► Subscribe► Subscribe
Teva
TAMOXIFEN CITRATE
tamoxifen citrate
TABLET;ORAL074504-001Apr 28, 2003DISCNNoNo► Subscribe► Subscribe► Subscribe
Ivax Sub Teva Pharms
TAMOXIFEN CITRATE
tamoxifen citrate
TABLET;ORAL075740-001Feb 20, 2003DISCNNoNo► Subscribe► Subscribe► Subscribe
Roxane
TAMOXIFEN CITRATE
tamoxifen citrate
TABLET;ORAL076027-001Feb 20, 2003DISCNNoNo► Subscribe► Subscribe► Subscribe
Pharmachemie
TAMOXIFEN CITRATE
tamoxifen citrate
TABLET;ORAL074539-001Mar 31, 2003DISCNNoNo► Subscribe► Subscribe► Subscribe
Actavis Labs Fl Inc
TAMOXIFEN CITRATE
tamoxifen citrate
TABLET;ORAL070929-002Feb 20, 2003ABRXNoNo► Subscribe► Subscribe► Subscribe
Astrazeneca
NOLVADEX
tamoxifen citrate
TABLET;ORAL017970-001Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: tamoxifen citrate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca
NOLVADEX
tamoxifen citrate
TABLET;ORAL017970-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Astrazeneca
NOLVADEX
tamoxifen citrate
TABLET;ORAL017970-002Mar 21, 1994► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: tamoxifen citrate

Country Document Number Estimated Expiration
JapanH1171269► Subscribe
Portugal893121► Subscribe
Austria214269► Subscribe
Denmark0893121► Subscribe
Spain2174388► Subscribe
European Patent Office0893121► Subscribe
Germany69804169► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Citi
US Army
Daiichi Sankyo
Johnson and Johnson
Medtronic
McKinsey
Federal Trade Commission
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot